SCHEMBL8907833

SCHEMBL8907833

CCCCCCCCCCCCCCOc1ccc([C]=O)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.51
THRB P10828 1/20 0.51
PLA2G4B P0C869 1/20 0.50
SMPD1 P17405 5/20 0.49
S1PR2 O95136 1/20 0.47
S1PR1 P21453 1/20 0.47
S1PR3 Q99500 1/20 0.47
LPAR2 Q9HBW0 1/20 0.47
PRSS1 P07477 2/20 0.46
CHUK O15111 1/20 0.45
DAPK3 O43293 1/20 0.45
JAK2 O60674 1/20 0.45
ROCK2 O75116 1/20 0.45
PRKCG P05129 1/20 0.45
CDK1 P06493 1/20 0.45
PIM1 P11309 1/20 0.45
RPS6KB1 P23443 1/20 0.45
CDK2 P24941 1/20 0.45
AKT1 P31749 1/20 0.45
AKT2 P31751 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7271422 1.00 THRA (0.51) THRATHRBPLA2G4BSMPD1S1PR2
SCHEMBL6194741 0.91 CHUK (0.46) THRATHRBPLA2G4BSMPD1S1PR2
SCHEMBL7996217 0.85 ALDH1A1 (0.50) THRATHRBPLA2G4BSMPD1PRSS1
SCHEMBL9524559 0.83 PDE4A (0.46) SMPD1HPGD
SCHEMBL9528325 0.83 FDPS (0.50) ALDH1A1HPGD
SCHEMBL2702025 0.82 MAPT (0.54) ALDH1A1HPGD
SCHEMBL9530159 0.81 KMT2A (0.50) PRSS1ALDH1A1
SCHEMBL8975125 0.79 THRA (0.53) THRATHRBPLA2G4BSMPD1S1PR2
SCHEMBL10723938 0.79 MEN1 (0.48) ALDH1A1
SCHEMBL2163665 0.78 AR (0.55) PLA2G4BPRKCDALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0662965-A1 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT SCHERING CORPORATION (US) 1995-07-19 EP claimed
US-5416118-A Enzyme inhibitors SCHERING CORPORATION (US) 1995-05-16 US claimed
WO-1994006784-A1 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT SCHERING CORPORATION (US) 1994-03-31 WO claimed
EP-0583346-A1 BICYCLIC AMIDES AS INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL ACYL TRANSFERASE SCHERING CORPORATION (US) 1994-02-23 EP claimed
EP-0514851-A1 N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase SCHERING CORPORATION (US) 1992-11-25 EP claimed
WO-1992018462-A1 BICYCLIC AMIDES AS INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL ACYL TRANSFERASE SCHERING CORPORATION (US) 1992-10-29 WO claimed
EP-0508425-A1 Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase SCHERING CORPORATION (US) 1992-10-14 EP claimed
US-5124337-A Treating atherosclerosis SCHERING CORPORATION (US) 1992-06-23 US claimed
US-5607931-A AMIDES SCHERING CORPORATION (US) 1997-03-04 US disclosed
EP-0662965-A1 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT SCHERING CORPORATION (US) 1995-07-19 EP disclosed
US-5416118-A Enzyme inhibitors SCHERING CORPORATION (US) 1995-05-16 US disclosed
US-5326762-A Heterocyclic substituted amides SCHERING CORPORATION (US) 1994-07-05 US disclosed
US-5321031-A Treating cardiovascular disorders SCHERING CORPORATION (US) 1994-06-14 US disclosed
WO-1994006784-A1 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT SCHERING CORPORATION (US) 1994-03-31 WO disclosed
US-5238935-A Treating atherosclerosis SCHERING CORPORATION (US) 1993-08-24 US disclosed
EP-0514851-A1 N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase SCHERING CORPORATION (US) 1992-11-25 EP disclosed
WO-1992018462-A1 BICYCLIC AMIDES AS INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL ACYL TRANSFERASE SCHERING CORPORATION (US) 1992-10-29 WO disclosed
EP-0508425-A1 Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase SCHERING CORPORATION (US) 1992-10-14 EP disclosed
US-5149709-A Treatment of atherosclerosis SCHERING CORPORATION (US) 1992-09-22 US disclosed
US-5124337-A Treating atherosclerosis SCHERING CORPORATION (US) 1992-06-23 US disclosed